pilocarpine has been researched along with Adverse Drug Event in 11 studies
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with pilocarpine hydrochloride tablets may improve saliva secretion in patients taking xerogenic medications and/or suffering from metabolic sialosis expanding the beneficial potential of this sialogogue." | 1.34 | Pilocarpine treatment in a mixed cohort of xerostomic patients. ( Aframian, DJ; Helcer, M; Livni, D; Markitziu, A; Nadler, C; Robinson, SD, 2007) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| CERANKE, P | 1 |
| TOMEK, S | 1 |
| Aframian, DJ | 1 |
| Helcer, M | 1 |
| Livni, D | 1 |
| Robinson, SD | 1 |
| Markitziu, A | 1 |
| Nadler, C | 1 |
| Wick, JY | 1 |
| Quigley, HA | 1 |
| Fox, PC | 1 |
| Stankiewicz, A | 1 |
| Boyd, EM | 1 |
| Drance, SM | 1 |
| Beccari, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray on the Relief of Dry Mouth Symptoms[NCT04186806] | 40 participants (Actual) | Interventional | 2019-11-02 | Completed | |||
| Multicenter, Controlled Parallel Groups Trial to Evaluate the Efficacy, Safety and Acceptability of OGT Oromucosal Spray Versus a Saliva Substitute in the Treatment of Xerostomia in Geriatrics[NCT00350350] | 74 participants (Actual) | Observational | 2003-10-31 | Completed | |||
| Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia[NCT00332618] | 74 participants | Observational | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 120 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.86 |
| Biotene Moisturizing Mouth Spray | 5.41 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 30 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.51 |
| Biotene Moisturizing Mouth Spray | 4.75 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 60 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.58 |
| Biotene Moisturizing Mouth Spray | 5.04 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 240 minutes post dose
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 5.14 |
| Biotene Moisturizing Mouth Spray | 5.68 |
Mean Visual Analog Scale (VAS) on the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms (NCT04186806)
Timeframe: 5 minutes
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.54 |
| Biotene Moisturizing Mouth Spray | 4.62 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 15 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.394 |
| Biotene Moisturizing Mouth Spray | -2.036 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 30 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.420 |
| Biotene Moisturizing Mouth Spray | -1.900 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 5 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.203 |
| Biotene Moisturizing Mouth Spray | -1.871 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 120 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.364 |
| Biotene Moisturizing Mouth Spray | -1.657 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 240 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M Dry Mouth Moisturizing Spray | -2.322 |
| Biotene Moisturizing Mouth Spray | -1.665 |
Paired-difference Visual Analog Scale (VAS) between both experimental and active control against water control. The range of possible values is -10 to +10. A negative value means is a better outcome than water. A positive value means is a worse outcome than water. (NCT04186806)
Timeframe: 60 minutes
| Intervention | cm (Least Squares Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | -2.455 |
| Biotene Moisturizing Mouth Spray | -1.833 |
Primary endpoint will be paired-difference in Visual Analog Scale (VAS) between experimental and active control product. On the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms. (NCT04186806)
Timeframe: 15 minutes post dose
| Intervention | cm (Mean) |
|---|---|
| 3M(TM) Dry Mouth Moisturizing Spray | 4.51 |
| Biotene Moisturizing Mouth Spray | 4.6 |
3 reviews available for pilocarpine and Adverse Drug Event
| Article | Year |
|---|---|
Xerostomia: causes and treatment.
Topics: Autoimmune Diseases; Bone Marrow Transplantation; Drug-Related Side Effects and Adverse Reactions; H | 2007 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
Management of dry mouth.
Topics: Aged; Aging; Drug-Related Side Effects and Adverse Reactions; Humans; Mouth; Mouth Diseases; Parasym | 1997 |
[Selected problems of pharmacology and toxicology of the eye].
Topics: Acetazolamide; Adrenal Cortex Hormones; Animals; Anti-Bacterial Agents; Drug-Related Side Effects an | 1970 |
8 other studies available for pilocarpine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
[Pilocarpine intoxication in heart block].
Topics: Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Heart Block; Humans; Piloc | 1953 |
Pilocarpine treatment in a mixed cohort of xerostomic patients.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Body Temperature; Cohort Studies; Dizziness; Drug-Re | 2007 |
A reevaluation of glaucoma management.
Topics: Acetazolamide; Cataract; Costs and Cost Analysis; Drug-Related Side Effects and Adverse Reactions; E | 1984 |
100-day LD 50 index of chronic toxicity.
Topics: Acetaminophen; Administration, Oral; Animals; Aspirin; Atropine; Caffeine; DDT; Drug-Related Side Ef | 1971 |
Medical management of glaucoma.
Topics: Acute Disease; Carbachol; Carbonic Anhydrase Inhibitors; Child; Cholinesterase Inhibitors; Chronic D | 1967 |
[DL50 and survival time].
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Mathematics; Mice; Physostigmine; Pilocarp | 1967 |